Comparative Pharmacology
Head-to-head clinical analysis: FLOVENT DISKUS 250 versus NYSTATIN TRIAMCINOLONE ACETONIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLOVENT DISKUS 250 versus NYSTATIN TRIAMCINOLONE ACETONIDE.
FLOVENT DISKUS 250 vs NYSTATIN-TRIAMCINOLONE ACETONIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluticasone propionate is a corticosteroid with potent anti-inflammatory activity. It binds to the glucocorticoid receptor, leading to inhibition of pro-inflammatory cytokines, reduction of eosinophil recruitment, and suppression of airway hyperresponsiveness.
Nystatin is a polyene antifungal that binds to ergosterol in the fungal cell membrane, forming pores that cause leakage of intracellular contents and cell death. Triamcinolone acetonide is a corticosteroid that induces phospholipase A2 inhibitory proteins (lipocortins), thereby inhibiting the release of arachidonic acid and reducing prostaglandin and leukotriene synthesis, leading to anti-inflammatory, antipruritic, and vasoconstrictive effects.
250 mcg inhaled orally via DISKUS twice daily (500 mcg total daily dose).
Apply topically to affected area twice daily for 2-4 weeks.
None Documented
None Documented
Approximately 10-12 hours (terminal elimination half-life in asthmatics).
Nystatin: negligible systemic half-life due to lack of absorption. Triamcinolone acetonide: terminal half-life ~2-5 hours (mean ~3.5 h) after intravascular administration; prolonged in hepatic impairment.
Renal (approximately 5% as unchanged drug); fecal (majority as metabolites and unabsorbed drug).
Nystatin: negligible systemic absorption; excreted unchanged in feces (~100%). Triamcinolone acetonide: metabolized hepatically; renal excretion of metabolites (~40%) and unchanged drug (<5%); fecal excretion (~60%).
Category C
Category D/X
Corticosteroid
Corticosteroid